黄龙咳喘胶囊治疗老年慢性支气管炎的疗效观察  

Clinical efficacy of Huanglongkechuan capsule on senile chronic bronchitis

作　　者：谭虎[1] 关健 刘冬[1] 

机构地区：[1]石河子大学医学院第一附属医院,石河子832008

出　　处：《中药药理与临床》2017年第5期183-186,共4页Pharmacology and Clinics of Chinese Materia Medica

摘　　要：目的:黄龙咳喘胶囊治疗老年慢性支气管炎的临床疗效。方法:106例来自石河子大学医学院第一附属医院的老年慢性支气管炎患者(2015.8--2016.12)随机原则分为对照组和观察组,各53例。两组均接受常规治疗,观察组另外给予黄龙咳喘胶囊。结果:10天为一个疗程,治疗3个疗程后,观察组疗效(94.34%)明显高于对照组(77.36%)。经治疗,两组血清炎症水平、血液流变学指标均下降,血气指标得以改善,观察组hs-CRP、TNF-ɑ、IL-8水平分别低于对照组(9.73±2.42)mg/L比(12.91±2.86)mg/L、(0.51±0.29)ng/ml比(0.92±0.35)ng/ml、(0.60±0.34)ng/ml比(1.05±0.39)ng/ml,观察组Pa CO2和Pa O2均明显优于对照组(44.93±4.16)mm Hg比(50.27±4.47)mm Hg、(89.83±7.05)mm Hg比(81.27±6.72)mm Hg,观察组全血粘度高切、全血粘度低切、血浆粘度分别低于对照组(4.59±0.41)m Pa·s比(5.16±0.50)m Pa·s、(7.83±0.60)m Pa·s比(8.95±0.71)m Pa·s、(1.57±0.12)m Pa·s比(1.83±0.14)m Pa·s。对照组不良反应总发生率为11.32%,和观察组9.43%比,差异无统计学意义。结论:黄龙咳喘胶囊可作为老年慢性支气管炎的辅助用药,其可增加慢性支气管炎治疗效果,改善患者血气、血液流变学,降低炎症,且较为安全。Objective： To analyse the clinical efficacy of Huanglongkechuan capsule on senile chronic bronchitis. Methods： 106 elderly patients with chronic bronchitis from The First Affiliated Hospital of Shihezi University Medical College（2015. 8 - 2016. 12） were grouped into the control group and the observation group,with 53 cases. Patients in two groups were treated with routine schemes and those in the observation group was treated addtionally with Huanglongkechuan capsule. Results： 10 days is a course of treatment,after 3 courses of treatment,the total efficiency in the observation group was 94. 34%,higher than that in the control group with 77. 36%（P〈0. 05）. After the treatment,serum inflammation and hemorheological indexes in two groups decreased,the blood gas index improved,and above indicators in the observation group were better than those in the control group（all P〈0. 05）. The hs-CRP,TNF-ɑ and IL-8 in the observation group were lower than those in the control group[（9. 73 ± 2. 42） mg/L vs（12. 91 ± 2. 86） mg/L,（0. 51 ± 0. 29） ng/ml vs（0. 92 ± 0. 35） ng/ml,（0. 60 ± 0. 34） ng/ml vs（1. 05 ± 0. 39） ng/ml（all P〈0. 05） ]. The Pa CO2 and Pa O2 in the observation group were better than those in the control group[（44. 93 ± 4.16） mm Hg vs（50. 27 ± 4. 47） mm Hg,（89. 83 ± 7. 05） mm Hg vs（81. 27 ± 6. 72） mm Hg（all P〈0. 05） ]. The whole blood high shear viscosity,low shear viscosity and plasma viscosity in the observation group were lower than those in the control group[4. 59 ± 0. 41） m Pa·s vs（5. 16± 0. 50） m Pa·s,（7. 83 ± 0. 60） m Pa·s vs（8. 95 ± 0. 71） m Pa·s,（1. 57 ± 0. 12） m Pa·s vs（1. 83 ± 0. 14） m Pa·s（all P〈0. 05） ]. The total incidence of adverse reactions in the control group was 11. 32%,and that in the observation group was 9. 43%,but there was no significant difference between two groups（P〉0. 05）. Conclusion： Huanglongkechuan capsule can assist to treat chronic bronchitis in the elder

关 键 词：黄龙咳喘胶囊 慢性支气管炎 老年患者 安全性 

分 类 号：R259[医药卫生—中西医结合]